HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

12 MONTH VULVAL CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copy of the 6 month CRF when completing this 12 month CRF: please complete any additional treatment details that were not captured at 6 months (for example, additional treatments, or end dates of those ongoing at 6 months)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID / /		
Participant's date of birth	у у у у	
Has the participant had any genetic tests f	or inherited cancers? (please tick on	e box)
Yes (already recorded in previous CRF)		
Yes (but not recorded in previous CRF)		
No		
Unknown		
If you answered "Yes (but not recorded in please provide some information about the completing the table(s) below		
Name of genetic test for cancer (1)	Result of genetic test	
	Positive	
	Negative	
	Ambiguous/uncertain Awaiting result	
	Unknown	
Name of genetic test for cancer (2)	Result of genetic test	
	Positive	
	Negative	
	Ambiguous/uncertain	
	Awaiting result	
	Unknown	

Participant's Study ID / /	
Has the participant developed any NEW co-morbidities (which were not rethe baseline or 6 month CRF)? (please tick all that apply) in the tables belowerleaf)	
Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other	
chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Participant's Study ID / /	
Participant's new co-morbidities continued	
Clinical diagnosis of depression	
Psychiatric Diagnosis (e.g. schizophrenia, bipolar disorder)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	
Other (please give details)	
Other (please give details)	
Is the participant pre or post menopause? (please tick one box)	
Pre menopause	
Post menopause	
Unknown	

Partic	ipant's Study ID	/	/		
What treat	ments has the participant	t received	since those capt	ured at 6 months	
			_		
-	ALL that apply and write of				
dates for a	ny treatments which were	ongoing	at 6 months (tabl	e continued over	leat).
Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Neo-adjuvant chemotherapy	Drug(s), please give details		/ / 20	// 20	
	Neo-adjuvant chemotherapy numb	per of cycles,			
Neo-adjuvant adiotherapy	External radiotherapy		/ / 20	// 20	
	Number of radiotherapy fractions,	please enter	on line		_
	Dose for each radiotherapy fractio	n please ento	er on line		
Surgery	Sentinel lymph node biopsy		/ / 20		
	Groin/inguinal lymph node dissection		// 20		
	Radical wide local		// 20		
	excision / Wide local				
	Radical partial vulvectomy /		/ / 20		
	Radical vulvectomy		/ / 20		

Pelvic exenteration

Vulval reconstruction

Plastics surgery (please describe)

Other surgery (please describe)

/__/ 20__

/__/ 20__

/__/ 20__

Participant's Study ID		,		/			
Participant's Study ID		/		/			

		(dd/mm/yyyy)	(dd/mm/yyyy)	completed as planned, please give a reason why	
Cisplatin		// 20	/ / 20		
Fluorouracil (5-FU)		// 20	// 20		
Mitomycin		// 20	// 20		
Carboplatin		/ / 20	// 20		
Paclitaxel/Taxol		/ / 20	/ / 20		
Capcitabine		/ / 20	/ / 20		
Other (please describe below):		/ / 20	// 20		
Chemotherapy number of cyc	cles, please e	nter on line	_		
External radiotherapy		// 20	// 20		
Number of radiotherapy fractions, please enter on line Dose for each radiotherapy fraction please enter on line					
Number of radiotherapy fractions, please enter on line					
Dose for each radiotherapy fraction please enter on line					
Other treatment e.g. clinical trial treatment (please describe)		// 20	/ / 20		
	Altomycin Carboplatin Carboplatin Caclitaxel/Taxol Capcitabine Other (please describe pelow): Chemotherapy number of cycle External radiotherapy Number of radiotherapy fra Dose for each radiotherapy Number of radiotherapy Dose for each radiotherapy Number of radiotherapy Number of radiotherapy Other treatment e.g. clinical trial treatment	Altomycin Carboplatin Caclitaxel/Taxol Capcitabine Other (please describe below): Chemotherapy number of cycles, please estatement External radiotherapy Number of radiotherapy fractions, pleas Brachytherapy Number of radiotherapy fractions, pleas Dose for each radiotherapy fractions, pleas Dose for each radiotherapy fractions, pleas Dose for each radiotherapy fractions, pleas Other treatment e.g. clinical trial treatment	Mitomycin	Aitomycin	

Participant's Study ID / / /
Has the participant had a local recurrence of their vulval cancer? (please tick one box) Yes No Unknown
If the participant has had a local recurrence, on what date was the recurrence diagnosed? d d y y y
Since the participant's diagnosis of vulval cancer, has there been any evidence of distant metastatic disease? (please tick one box)
Yes No Unknown
If you have answered "yes" to the above question, on what date was the metastatic disease diagnosed:
Please provide details of the site(s) of distant metastatic disease:
Yes No Unknown
If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in Name of clinical trial

Participant's Study ID /			
Since the participant's diagnosis of vulval canother new primary cancer? (please tick o			
Yes No	Unknown		
If you answered "yes" to the above question about the participant's new cancer diagno			
Type of cancer			
Date of diagnosis	// 20		
Treatment received			
Date treatment ended (if finished)	// 20		
What type of follow-up care is the partici	pant receiving? (please tick ONE box)		
Routine/regular hospital clinic based folloface-to-face or by telephone)	ow-up (medical or nurse led,		
Primary care based follow-up			
Patient initiated follow-up (also known a (PTFU), open access follow-up, or suppor			
If the participant is receiving patient-inition they discharged to this?	iated follow-up, on what date were		

Participant's Study ID / /
Has the participant been referred to any of the following services and/or had a Holistic Needs Assessment? (please tick all that apply)
Participant has been referred to palliative care services
Participant has been referred to psychological services If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies)
Participant has been referred to community services
Participant has been referred for treatment related problems (e.g. urology, gastroenterology) If ticked, please provide more details below:
Participant has had an HNA (holistic needs assessment)
If the participant has died please give the date and cause of death: Participant's date of death d d / m m / y y y y Cause of participant's death
1) a)
1) b)
1) c)
2)
Cause of death not known
Please add your name and signature and the date that you completed this CRF
Name Signature
Date CRF completed